Alpha 2.0
Login Register
» Authors » Mohamed El Missiry

Mohamed El Missiry

Explore the profile of Mohamed El Missiry including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 88
Followers 0
Related Specialties
Oncology
General Medicine
Pediatrics
Top 10 Co-Authors
Satu Mustjoki
Kimmo Porkka
Henrik Hjorth-Hansen
Cornelio Uderzo
Leif Stenke
Lawrence Faulkner
Anna Kreutzman
Ulla Olsson-Stromberg
Fatima Itrat
Johan Richter
Published In
J Cancer Res Clin Oncol
J Am Med Inform Assoc
PLoS One
Anemia
J Pediatr Hematol Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival
Bruck O, Dufva O, Hohtari H, Blom S, Turkki R, Ilander M, et al.
Blood Adv . 2020 Jan; 4(2):274-286. PMID: 31968078
The immunologic microenvironment in various solid tumors is aberrant and correlates with clinical survival. Here, we present a comprehensive analysis of the immune environment of acute myeloid leukemia (AML) bone...
2.
Low Expression of miR-18a as a Characteristic of Pediatric Acute Lymphoblastic Leukemia
Mosakhani N, Missiry M, Vakkila E, Knuutila S, Vakkila J
J Pediatr Hematol Oncol . 2017 Oct; 39(8):585-588. PMID: 29068867
Background: Acute lymphoblastic leukemia (ALL) occurs in both adults and children but the response to chemotherapy and survival is significantly worse in the adults. We aimed to study whether the...
3.
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia
Rajala H, Missiry M, Ruusila A, Koskenvesa P, Brummendorf T, Gjertsen B, et al.
J Cancer Res Clin Oncol . 2017 Mar; 143(8):1543-1554. PMID: 28337541
Purpose: Tyrosine kinase inhibitors (TKIs) have well-characterized immunomodulatory effects on T and NK cells, but the effects on the humoral immunity are less well known. In this project, we studied...
4.
Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia
Missiry M, Hjorth-Hansen H, Richter J, Olson-Stromberg U, Stenke L, Porkka K, et al.
PLoS One . 2017 Jan; 12(1):e0171041. PMID: 28135325
In chronic myeloid leukemia (CML), early treatment prediction is important to identify patients with inferior overall outcomes. We examined the feasibility of using reductions in BCR-ABL1 transcript levels after 1...
5.
Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia
Missiry M, Adnan Awad S, Rajala H, Al-Samadi A, Ekblom M, Markevan B, et al.
J Cancer Res Clin Oncol . 2016 Jan; 142(5):1041-50. PMID: 26746653
Purpose: Tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukaemia have been reported to induce immunomodulatory effects. We aimed to assess peripheral blood (PB) and bone marrow...
6.
Assessment of serum zinc levels of patients with thalassemia compared to their siblings
Missiry M, Hussein M, Khalid S, Yaqub N, Khan S, Itrat F, et al.
Anemia . 2014 Sep; 2014:125452. PMID: 25197566
Zinc (Zn) is essential for appropriate growth and proper immune function, both of which may be impaired in thalassemia children. Factors that can affect serum Zn levels in these patients...
7.
A prospective international cooperative information technology platform built using open-source tools for improving the access to and safety of bone marrow transplantation in low- and middle-income countries
Agarwal R, Sedai A, Dhimal S, Ankita K, Clemente L, Siddique S, et al.
J Am Med Inform Assoc . 2014 Apr; 21(6):1125-8. PMID: 24714444
Jagriti Innovations developed a collaboration tool in partnership with the Cure2Children Foundation that has been used by health professionals in Italy, Pakistan, and India for the collaborative management of patients...